Hertraz 150mg is used for the treatment of Supportive treatment for breast cancer The drug Hertraz 150mg is used for the treatment of Advanced breast cancer The drug Hertraz 150mg is used for the treatment of Advanced gastric cancer
Hertraz 150mg injection be expressed by a targeted cancer drug known as Trastuzumab, which is Pharmacologically classify as humanized monoclonal antibody produced by recombinant DNA technology. Hertraz 150mg helps to decrease the rate of reactivation & mortality. One of the epidermal growth factor receptor is known as human epidermal growth factor receptor 2 (HER2) plays vital role in breast cancer.
This factor is responsible for cell replication. An FDA approved product Hertraz 150mg which is involved in breast cancer treatment. Hertraz 150mg vial with 858mg of lyophilized powder containing 150mg of Trastuzumab
The drug Hertraz 150mg is used for the treatment of Supportive treatment for breast cancer The drug Hertraz 150mg is used for the treatment of Advanced breast cancer The drug Hertraz 150mg is used for the treatment of Advanced gastric cancer
MECHANISM OF ACTION
Hertraz 150mg is a type of monoclonal antibody which targeting the HER2, provoke a resistant mediate reaction which causes disguise and down regulation of HER2. HER2 pathway is specific for cell proliferation, joining of Transtuzumab to the site of HER2 causes prevention of this activity. This joining leads to antibody mediated and leads to HER2 positive cells break down. Hertraz 150mg is a intermediary of anti-body dependent cellular cytotoxicity. Distribution: Volume of distribution: 44 mL/kg as trastuzumab; 3.13 L as trastuzumab emtansine. Metabolism: As trastuzumab emtansine: which Undergoes deconjugation and catabolism through proteolysis in cellular lysosomes. Excretion: Terminal Elimination half-life is 6 days (weekly dosing); 16 days (3 weekly regimen); approx 4 days as trastuzumab emtansine. Elimination of drug includes clearance of IgG through the reticuloendothelial system.
Adjuvant regimen for HER2 over expressing Breast cancer:
52 weeks of treatment total schedules as follows: Combination With paclitaxel or docetaxel ,over a 90 minutes, 4mg/kg IV then over 30 minutes , 2mg /kg for 12 weeks or combination with Carboplatin/ docetaxel for 18 weeks one week following the last weekly dose. Over 30 to 90 minutes, 6mg/kg IV for every 3 weeks.
ESOPHAGEAL CARCINOMA OR GASTRIC CANCER FOR ADULT DOSE:
8mg/kg IV over 90 minutes as initial dose 6mg/kg IV over 30 to 90 minutes for every 3 weeks as maintenance dose Duration of therapy for initial and maintenance dose until disease progression.
BREAST CANCER METASTATIC HER2-OVEREXPRESSING:
Over a 90 minutes, 4mg/kg alone or with combination of paclitaxel in initial dose. Over 30 minutes, 2mg /kg once in a week for maintenance dose. Duration of therapy for initial and maintenance dose until disease progression.
Hertraz 150mg is administer into vein through IV infusion over 90 minutes Do not administer IV push or bolus. Duration of Hertraz 150mg is administrated in once every week or every 3 weeks. Before starting treatment, patients should undergo biopsy to check Hertraz 150mg is the right regimen The infusion solution should be compatible to polyvinyl chloride or polyethylene bags. After dilution, the infusion bag should be stored at 2oC to 8oC for not more than 24 hours before use.
EMBRYO FETAL DAMAGE
Hertraz 150mg is contraindicated to pregnancy period. Avoid becoming pregnancy during this therapy. Use efficient contraceptives during treatment
Hertraz 150mg receiving patients have increased risk of exposing to cardiac disorders. Provide alternative therapy management In serious condition, treatment should be discontinue
Some serious fatal cases of pulmonary toxicity occur during Hertraz 150mg treatment.
During Hertraz 150mg treatment some life threatening infusion reactions are produced. In serious infusion reactions, Stop the Hertraz 150mg treatment permanently. Patient should be treated with premedication before starting the infusion to overcome the such problem, During Hertraz 150mg treatment.use with Caution.
THERAPY INDUCED NEUTROPENIA
Higher incidence of neutropenia occurs during Hertraz 150mg treatment.
THE MOST COMMON ADVERSE EFFECTS
Embryo fetal toxicity
Chemotherapy induced neutropenia
THE MOST COMMON SIDE EFFECTS
In some phenomenal condition, patient should get anthracycline, in that situation patient’s cardiac function should be checked carefully with regular intervals. Do not take anthracycline treatment for 7 months after stopping the Hertraz 150mg treatment. Hertraz 150mg interaction with anthracycline after ending of Hertraz 150mg treatment may have a chance of getting cardiac problem. This side effects occur because of Transtuzumab great disaster period is depends on population PK analysis.
Probably no contraindicated occurs. The patients are contraindicated to the component present in the Hertraz 150mg , Hence Hypersensitivity reactions are occurs. Infusion reactions are produced.
PREGNANCY & LACTATION
Hertraz 150mg pregnancy category is D: Hertraz 150mg should not suggest during pregnancy condition. Breast feeding should not be recommended.
Hertraz 150mg vials should be stored at refrigerator temperature of 2°C to 8°C Keep the vial away from heat & light After reconstitution, vial should be stored at 2°C to 8°C for 28 days. Stored Hertraz 150mg diluted bag at 2°C to 8°C for 24 hours
If missed cycles of Hertraz 150mg treatment by one week or less, then the repeated maintenance dose (weekly schedule: 2mg/kg; 3 weekly schedule: 6mg/kg) administer as soon as probably. Until the next planned cycle the patient does not take interval. Consecutive Hertraz 150mg maintenance dose should be taken in 7 days or 21 days next confer to the weekly or 3 weekly schedules. If patient missed to take Hertraz 150mg dose by higher than one week, then resume with re-storing dose of Hertraz 150mg such as weekly schedule is 4mg/kg; 3 weekly schedules is 8mg/kg should be administered over period of 90 minutes.